Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study.
Kim van Oorsouw, S. W. Toennes, J. G. Ramaekers
Psychopharmacology (Berl) January 24, 2022 DOI: 10.1007/s00213-021-06046-9 via PubMed Central
Summary
AI-generated from the abstractIn 20 clinically depressed patients, a single ayahuasca ceremony was followed by reduced depressive symptoms that persisted for up to one year. Average Beck's Depression Inventory scores dropped from 22.7 before the ceremony to 8.88 at one-year follow-up. Remission rates were 12 out of 20 after one day, 13 out of 19 after one month, and 12 out of 17 after one year. Three participants remained mildly depressed at one month and one year; two did not respond and stayed at moderate or severe levels. Improvements in depression and mental health correlated with the degree of ego dissolution experienced during the ceremony. Additional treatments or psychedelic use may have contributed to long-term gains. Ayahuasca shows therapeutic potential for clinical depression.
Study at a glance
| Characteristics | Observational study Longitudinal Peer reviewed |
|---|---|
| Sample size | 20 |
| Population | Clinically depressed patients with Beck's Depression Inventory scores above 13 |
| Intervention | Ayahuasca |
| Duration | Single ceremony, with follow-ups at 1 day, 1 month, and 1 year |
| Topics | Ayahuasca Psychedelic-assisted therapy |
| Keywords | Depression treatment Antidepressant Mood disorder therapy Mental health treatment Depressive symptom relief |
| Citations | 71 |
| Key finding | Ayahuasca was followed by sustained reductions in depressive symptoms and high remission rates up to one year after a single ceremony. |
Abstract
RATIONALE: Studies have suggested mental health improvements following the use of the psychotropic plant concoction ayahuasca in non-clinical and clinical samples. OBJECTIVES: The present observational study assessed depressive symptomatology in 20 clinically depressed patients (symptom score > 13 on the Beck's Depression Inventory) before attendance of an ayahuasca ceremony and 1 month and 1 year after. Secondary measures included ratings of altered states of consciousness and ego dissolution during the ayahuasca ceremony as well as global measures of mindfulness, satisfaction with life, depression, anxiety, and stress. RESULTS: Twenty participants completed baseline and 1-day follow-up, 19 completed measures at 1-month follow-up, and 17 completed measures at 1-year follow-up. BDI scores reduced from baseline (M = 22.7) to all post-ceremony measures (Ms 11.45, 12.89, and 8.88, for 1-day, 1-month, and 1-year follow-up, respectively). After 1 day, 12/20 participants were in remission (BDI < 13). Remission rates after 1 month and 1 year were 13/19 and 12/17, respectively. Three participants remained mildly depressed (BDI 14-19) at the 1-month and 1-year follow-up. Two participants did not respond and remained at a moderate/severe level of depression at 1-year follow-up. Reductions on the secondary mental health measures and increases in mindfulness and satisfaction with life were found up to 1 year post-ceremony. Improvements in clinical depression and mental health correlated with levels of experienced ego dissolution and oceanic boundlessness during the ceremony up to 1 month after the ceremony. Engagement in additional mental health treatments or use of another psychedelic during study participation may have contributed to improved mental health ratings at 1-year follow-up. CONCLUSION: Ayahuasca produces long-term mental health improvements in clinically depressed patients, which highlights its therapeutic potential.